Henry Sicignano III, M.B.A., MBA Net Worth

Mr. Henry Sicignano III, M.B.A., MBA biography

Henry Sicignano III, M.B.A., MBA is the Consultant at 22nd Century Inc.

How old is Mr MBA?

Mr MBA is 53, he's been the Consultant of 22nd Century Inc since . There are 10 older and 2 younger executives at 22nd Century Inc. The oldest executive at 22nd Century Group Inc is Roger O'Brien, 71, who is the Independent Director.

What's Mr MBA's mailing address?

Henry's mailing address filed with the SEC is 9530 MAIN STREET, , CLARENCE, NY, 14031.

Insiders trading at 22nd Century Inc

Over the last 11 years, insiders at 22nd Century Inc have traded over $3,035,006 worth of 22nd Century Inc stock and bought 652,225 units worth $737,196 . The most active insiders traders include Andrew Arno, Joseph Pandolfino, and Michael Zercher. On average, 22nd Century Inc executives and independent directors trade stock every 80 days with the average trade being worth of $16,372. The most recent stock trade was executed by Lawrence Firestone on 30 May 2024, trading 9,000 units of XXII stock currently worth $9,810.

What does 22nd Century Inc do?

with the mission of reducing the harm caused by smoking, 22nd century is a plant biotechnology company whose proprietary technology allows for the levels of nicotine in the tobacco plant to be decreased or increased through genetic engineering and plant breeding. goodrich tobacco company and hercules pharmaceuticals are wholly-owned subsidiaries focusing on (i) premium cigarettes and potentially reduced risk tobacco products (with up to 97% less nicotine than conventional cigarettes), and (ii) the x-22 prescription smoking cessation aid in development. 22nd century's technology also allows the levels of cannabinoids to be decreased or increased in the cannabis plant.

22nd Century Inc executives and stock owners

22nd Century Inc executives and other stock owners filed with the SEC include:

• James A. Mish,
  Chief Exec. Officer
• Michael J. Zercher,
  Pres & COO
• John Brodfuehrer,
  Vice President - Strategy
• John E. Franzino,
  Chief Admin. Officer
• Nora Sullivan,
  Chairman of the Board
• Michael Koganov,
  Independent Director
• James Mish,
  Chief Executive Officer
• John Franzino,
  Chief Financial Officer
• Mei Kuo,
  Director of Communications and Investor Relations
• Lisa Parks,
  Vice President - Acquisitions
• Roger O'Brien,
  Independent Director
• Richard Sanders,
  Independent Director
• Juan Tamburrino,
  Vice President - Research & Development
• Michael Zercher,
  President, Chief Operating Officer
• Dr. Calvin Treat,
  Chief Scientific Officer
• R. Hugh Kinsman,
  Chief Financial Officer
• James C. Morrison,
  Technical Advisor & Regulatory Affairs Consultant
• Henry Sicignano III, M.B.A., MBA,
  Consultant
• Steven Przybyla,
  VP, Gen. Counsel & Corp. Sec.
• Richard F. Fitzgerald CPA, CPA,
  Chief Financial Officer
• Lucille S Salhany,
  Director
• Andrew Arno,
  Director
• Joseph A Dunn,
  Director
• Paul Rushton,
  VP of Plant Biotechnology
• James E. Swauger,
  Senior VP-Science & Regulatory
• Thomas L. James,
  VP, General Counsel & Sec'y.
• Henry Iii Sicignano,
  President and Secretary
• Michael Robert Moynihan,
  Vice President of R&D
• James W Cornell,
  Director
• Joseph Pandolfino,
  Chief Executive Officer
• Partners, Llc Clearwater,
  10% owner
• Richard G Saffire,
  10% owner
• Clifford B Fleet,
  Director
• Andrea S Jentsch,
  Chief Financial Officer
• Richard F Fitzgerald,
  Chief Financial Officer
• Anthony L. Johnson,
  Director
• Peter Ferola,
  Chief Legal Officer & Secy.
• John J Miller,
  President, Tobacco
• Robert Hugh Kinsman,
  Chief Financial Officer
• Lawrence Firestone,
  Chief Executive Officer